Gujarat Themis Biosyn signed Asset Purchase Agreement with Sanofi to acquire 13 anti-TB and anti-infective brands for €158 million cash consideration.
Acquired portfolio reported net sales of €62 million in FY25 and has strong presence across 55+ countries in Europe, Middle East and Africa.
Transaction expected to close by December 2026 pending antitrust and foreign investment approvals in applicable jurisdictions.
Asset-light expansion provides immediate access to regulated markets and strengthens GTBL's global generic pharmaceuticals platform.